They say lightning rarely strikes twice but Kezar Life Sciences has suffered its second clinical blow in as many months.

Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

Medical advances and better knowledge of health have contributed to increased life expectancy and a growing elderly ...

Longboard has commenced the Phase III DEEp OCEAN Study of bexicaserin for treating seizures linked to DEEs in two years and ...

At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...

R327G is a topical gel treatment being analysed for diabetic foot infections. Credit: Olga Apanasenko/Shutterstock. Recce ...

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it ...

Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured ...

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to treat ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...